DR. UTKARSH CHRIS SHUKLA MD
Prescription History 1437656154
Radiology - Radiation Oncology in Albuquerque, NM


Quality Rating: 85.27 out of 100 score

NPI Status: Active since April 09, 2018

Contact Information

4901 LANG AVE NE
ALBUQUERQUE, NM
ZIP 87109
Phone: (505) 842-8171

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. UTKARSH CHRIS SHUKLA MD, an active Radiation Oncology specialist practicing in Albuquerque, NM. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 12 documented patient claims. Among these therapy options, the most frequently utilized medication is Mometasone Furoate, which accounts for 12 claims alone.

Medication Index

No matching medications currently found on file.

Mometasone Furoate

Generic Formulation: Mometasone FuroateSpecialty: Radiation Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.5
Days Supply 261
NM State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills32.3
Peer Average Days Supply780
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.1% less volume than the regional standard for practitioners inside NM. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $258.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.51

State Avg Cost Per Claim

$45.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pregnadienediol derivative ANTI-ALLERGIC AGENT and ANTI-INFLAMMATORY AGENT that is used in the management of ASTHMA and ALLERGIC RHINITIS. It is also used as a topical treatment for skin disorders.

Therapeutic Applications

Mometasone is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. Mometasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. UTKARSH CHRIS SHUKLA MD provides transparency into local medical care patterns within Albuquerque, NM.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Radiation Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.